| Overview |
| bs-5077R |
| Ceramide synthase 2 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Ceramide synthase 2 |
| 201-300/380 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 29956 |
| Q96G23 |
| Cytoplasm, Nucleus, Cell membrane |
| L3; LASS2; SP260; TMSG1; Ceramide synthase 2; CerS2; LAG1 longevity assurance homolog 2; Tumor metastasis-suppressor gene 1 protein |
| LASS2 (LAG1 homolog, ceramide synthase 2) has sequence similarity to yeast longevity assurance gene 1. It is thought to be involved in sphingolipid synthesis. Expression of LASS2 is transiently increased during the period of active myelination and is specifically localized to white matter tracts of the brain, including the Schwann cells of sciatic nerves suggesting that LASS2 is important for the synthesis of dihydroceramide used for synthesis of myelin sphingolipids. Expression of LASS2 in hepatocellular carcinoma cell lines suppresses the growth of cancer cells. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz